ACIP Votes to Loosen Universal Hepatitis B Birth-Dose Recommendation

A federal vaccine advisory panel voted in early December 2025 to end the universal recommendation that all newborns receive the hepatitis B vaccine at birth. Under the change, the decision for infants born to mothers who test negative for the hepatitis B virus would shift to individual decision-making between parents and clinicians, with a suggestion that the first dose be considered no earlier than two months of age. The vote came from the Advisory Committee on Immunization Practices, which makes recommendations to the Centers for Disease Control and Prevention.

What the Change Would Do

For decades, the birth dose has been a cornerstone of hepatitis B prevention. Health officials have long pointed to it as the most effective way to stop transmission from mother to child during birth and early infancy, when infection is most likely to become chronic. Chronic hepatitis B can lead to liver cancer and cirrhosis later in life. The vaccine is considered safe and highly effective, and it has been part of the standard childhood schedule in the United States since the 1990s.

Supporters of the revised approach argued that many infants born to mothers who test negative face very low risk of exposure in the first months of life, and that parents should have more say in timing. Critics, including many pediatric and infectious disease groups, countered that the birth dose protects babies in situations where mothers' status may be unknown, missed, or changed, and that delayed doses can result in lost opportunities to vaccinate.

Process and Next Steps

An ACIP vote does not take effect on its own. Recommendations generally require sign-off from the CDC director before they become official federal guidance, and insurers and state immunization programs often reference that guidance when deciding coverage and school requirements. The panel's shift has also drawn attention because of broader changes to its membership and leadership in 2025, which prompted questions from medical societies about how evidence is reviewed.

Several professional organizations, including the American Academy of Pediatrics, have said they will continue to recommend the birth dose for all newborns and have issued their own immunization schedules. That split means parents may encounter different advice depending on whether they consult their pediatrician, a state health department, or federal materials.

Why It Matters

Vaccination rates for hepatitis B in infants have been high in the United States, and the birth dose has been credited with sharply reducing new childhood infections over the past three decades. Public health researchers say that any weakening of universal recommendations could create gaps, particularly for families with limited access to prenatal testing, follow-up care, or consistent pediatric visits.

Health systems are now weighing how to update patient materials, electronic records, and billing rules. Pharmacies, hospitals, and state officials may also need to clarify which recommendation applies in their jurisdictions. Pediatricians have said they expect many conversations with parents in the coming months about timing and the reasons behind the birth dose.

What to Watch

Key questions include whether the CDC formally adopts the panel's recommendation, how states and insurers respond, and whether vaccination rates for newborns change in the years ahead. Public health officials will be watching hepatitis B screening rates among pregnant women as well, since prenatal testing remains central to identifying infants who need the birth dose regardless of federal guidance.